Financial Performance & Goals - The company reported strong 1H 2025 results with net sales of $97 billion and expects ~$20 billion for the full year[23] - The company aims for a 10%+ organic revenue CAGR from 2026E-2028E[26, 41] - The company targets ~+50bps annual adjusted operating margin expansion from 2026E-2028E[26, 41] - The company anticipates leveraged annual adjusted EPS growth from 2026E-2028E[26, 41] - The company projects ~70-80% free cash flow conversion from 2026E-2028E[26, 41] Business Segment Highlights - Urology's served market is ~$7 billion and is expected to grow at ~7% over the long-range plan[76] - Neuromodulation's served market is ~$4 billion and is expected to grow at ~7% over the long-range plan[57] - Endoscopy's served market is ~$8 billion and is expected to grow at ~6% over the long-range plan[97] - Cardiovascular's served market is ~$50 billion and is expected to grow at ~9% over the long-range plan[113] International Markets - International markets account for ~35% of the company's 2025E revenue in high-single-digit growth markets[45] - The company's China revenue is expected to reach ~$12 billion in 2025[48]

Core Insights - AbbVie is actively engaging with the administration regarding drug pricing policies and is optimistic about the productive nature of these discussions [3][4]. Group 1: Company Overview - AbbVie is represented by its entire management team at the Goldman Sachs 46th Annual Global Healthcare Conference [1]. - Robert A. Michael, CEO & Director, emphasizes the importance of addressing affordability and access to medicines while maintaining innovation [4]. Group 2: Industry Environment - The pharmaceutical sector is currently facing uncertainties related to drug pricing policies, particularly following the Most Favored Nation Executive Order [3]. - The administration's engagement with the pharmaceutical industry is seen as a positive development, indicating a willingness to discuss various topics related to drug pricing and access [4].